openPR Logo
Press release

Novo Nordisk A/S (NYSE: NVO) Notice: Investigation for Investors in formerly Emisphere Technologies, Inc. (OTC: EMIS) over Takeover

02-16-2021 08:35 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors of formerly Emisphere Technologies, Inc. (OTC: EMIS) in connection with the takeover.

An investigation on behalf of investors of formerly Emisphere Technologies, Inc. (OTC: EMIS) in connection with the takeover.

An investigation was announced concerning potential securities laws violations in connection with the takeover of Emisphere Technologies, Inc. by Novo Nordisk A/S (NYSE: NVO).

Investors who purchased shares of Emisphere Technologies, Inc. (OTC: EMIS) and currently hold any of those OTC: EMIS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of Emisphere Technologies, Inc. breached their fiduciary duties owed to former OTC: EMIS investors in connection with the acquisition of Emisphere Technologies, Inc by Novo Nordisk A/S.

Roseland, NJ based Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. On November 06, 2020, Emisphere Technologies, Inc. announced that it has entered into an agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere Technologies, Inc. on a cash-free, debt-free basis, for $1.35 billion in cash. The consideration to be paid per share will depend on the amount of cash and debt at closing, but the Company currently estimates it to be approximately $7.82 per share based on approximately 170.9 million fully diluted shares outstanding. On December 8, 2020, Emisphere Technologies, Inc. announced the completion of the transaction whereby Novo Nordisk A/S acquired Emisphere.

Those who were investors in Emisphere Technologies, Inc. (OTC: EMIS) shares have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Novo Nordisk A/S (NYSE: NVO) Notice: Investigation for Investors in formerly Emisphere Technologies, Inc. (OTC: EMIS) over Takeover here

News-ID: 2243467 • Views:

More Releases from Shareholders Foundation

Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, 2025
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd. Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm

All 5 Releases


More Releases for Emisphere

Thermosetting Resin Polymerization Inhibitor Market: Revenue Growth is Making Ma …
Stratagem Market Insights has recently released an exclusive report entitled "Thermosetting Resin Polymerization Inhibitor Market: Global Opportunity Analysis and Industry Forecast, 2023-2030". The report provides a comprehensive analysis of the key factors influencing market growth, including key market players, current market developments, and emerging trends. It delves into a thorough study of the key determinants of the global market, including drivers, challenges, restraints, and upcoming opportunities. The report covers the driving
Insulin Detemir Market to Witness Remarkable Growth by 2027 | Novo Nordisk, MNKD …
Insulin detemir, sold under the brand name Levemir among others, is a long-acting insulin used to treat both sort 1 and type 2 diabetes. It is utilized by infusion under the skin. It is viable for as long as 24 hours. Normal incidental effects incorporate low glucose, hypersensitive responses, torment at the site of infusion, and weight acquire. Request Sample Copy of Insulin Detemir Market Report: https://www.infinitybusinessinsights.com/request_sample.php?id=598933 Top Key Players Included in
Oral Biologics Market – Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceutica …
Oral Biologics Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities and application landscape of the Oral Biologics depending on the industry's financial and non-financial impact. The complete range of information related to the Global Oral Biologics Market is obtained through
Investigation announced for Investors in shares of Emisphere Technologies, Inc. …
An investigation was announced concerning whether the takeover of Emisphere Technologies, Inc. is unfair to OTC: EMIS stockholders. Investors who purchased shares of Emisphere Technologies, Inc. (OTC: EMIS) and currently hold any of those OTC: EMIS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of Emisphere Technologies, Inc. breached their
What's driving the Insulin Detemir Market Growth? Prominent Players: Novo Nordis …
Global "Insulin Detemir Market" 2020 Industry Research Report is an expert and inside and out examination on the flow condition of the Global Insulin Detemir industry. In addition, investigate report sorts the worldwide Insulin Detemir market by top players/brands, area, type and end client. This report likewise examines the different Factors impacting the market development and drivers, further reveals insight into market review, key makers, key received by them, size,
Anticoagulant Drug Market: Comprehensive study explores Huge Growth in Future| A …
HTF MI recently introduced Global Anticoagulant Drug Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which are accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Astrazeneca, Bristol-Myers Squibb CO, Armetheon Inc, Emisphere Technologies, Sun Pharmaceuticals, Abbott